| Symbol | ATOS |
|---|---|
| Name | ATOSSA THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 107 SPRING STREET, SEATTLE, Washington, 98104, United States |
| Telephone | +1 206 325-6068 |
| Fax | — |
| — | |
| Website | https://www.atossatherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The companys drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use. Additional info from NASDAQ: |
(30% Negative) ATOSSA THERAPEUTICS, INC. (ATOS) Announces Clinical Development Update
Read moreAtos Advances AI-Ready Digital Transformation with Lumen Network as a Service
Read moreDaniel Mark James 🟢 acquired 63.0K shares of ATOSSA THERAPEUTICS, INC. (ATOS) Transaction Date: Mar 26, 2026 | Filing ID: 132644
Read moreNew Form ARS - ATOSSA THERAPEUTICS, INC. <b>Filed:</b> 2026-03-30 <b>AccNo:</b> 0001193125-26-131954 <b>Size:</b> 1 MB
Read moreNew Form DEF 14A - ATOSSA THERAPEUTICS, INC. <b>Filed:</b> 2026-03-30 <b>AccNo:</b> 0001193125-26-131807 <b>Size:</b> 8 MB
Read moreAtossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
Read more(30% Negative) ATOSSA THERAPEUTICS, INC. (ATOS) Reports Q1 2026 Financial Results
Read moreNew Form 10-K - ATOSSA THERAPEUTICS, INC. <b>Filed:</b> 2026-03-25 <b>AccNo:</b> 0001193125-26-124396 <b>Size:</b> 8 MB
Read more(99% Neutral) Atossa Therapeutics Inc. (ATOS) Announces Business Combination
Read moreNew Form 424B5 - ATOSSA THERAPEUTICS, INC. <b>Filed:</b> 2026-02-20 <b>AccNo:</b> 0001193125-26-061388 <b>Size:</b> 532 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04616430 | Topical Endoxifen in Women | Phase2 | Mammographic Breast Density | Completed | 2018-04-09 | 2019-09-04 | ClinicalTrials.gov |
| NCT02218385 | ForeCYTE Breast Aspirator for Sample Collection and Cytological Testing of Nipp… | — | Breast Neoplasms | Completed | 2014-08-01 | 2014-08-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| goserelin | DRUG | Phase PHASE2 | Breast Neoplasms | RECRUITING | NCT05607004 |
| (Z)-endoxifen | DRUG | Phase PHASE2 | Breast Neoplasms | RECRUITING | NCT05607004 |
| Z-Endoxifen | DRUG | Phase PHASE2 | Breast Density | ACTIVE_NOT_RECRUITING | NCT05068388 |
| Placebo | DRUG | Phase PHASE2 | Breast Density | ACTIVE_NOT_RECRUITING | NCT05068388 |
| Topical endoxifen | DRUG | Phase PHASE2 | Mammographic Breast Density | COMPLETED | NCT04616430 |
| AT-301A | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04519788 |
| AT-301B | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04519788 |
| Fulvestrant | DRUG | Phase PHASE2 | Female Breast Carcinoma | TERMINATED | NCT02540330 |
| ForeCYTE Breast Aspirator | DEVICE | Phase PHASE3 | Breast Cancer, Preneoplastic Conditions, BRCA | WITHDRAWN | NCT02539615 |
| Blood draw | DEVICE | Preclinical | Breast Cancer | COMPLETED | NCT02121873 |
| Ductal lavage microcatheter | DEVICE | Preclinical | Breast Cancer | COMPLETED | NCT02121873 |
| Nipple aspirator | DEVICE | Preclinical | Breast Cancer | COMPLETED | NCT02121873 |